| アブストラクト | We explored potential differences in time trends of gabapentinoid prescription and of opioid coprescription between 1993 and 2017 in the 4 UK nations using the Clinical Practice Research Datalink, a UK primary care database. There were distinct trends in annual rates of new gabapentin and pregabalin prescriptions in Northern Ireland. The rate of new gabapentin prescriptions rapidly increased after 2010 and exceeded that of the other nations by 2017 (rate of 836 [95% confidence interval: 787-887] per 100 000 person-years). Additionally, the rate of new pregabalin prescriptions was higher during the entire study period, reaching a peak of 1139 (95% confidence interval: 1088-1193) per 100 000 person-years in 2010, 5-fold higher than the other nations. Findings in Northern Ireland may be partly attributable to the high burden of anxiety disorders, an indication for pregabalin. Further exploration of reasons for discrepancies in gabapentinoid prescribing between UK nations is warranted. |
|---|
| 組織名 | Department of Epidemiology, Biostatistics and Occupational Health, McGill;University, Montreal, Canada.;Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research,;Jewish General Hospital, Montreal, Canada.;Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland,;UK.;Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and;Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine,;Toulouse, France.;INSERM, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug;Safety, CIC 1426 - University Paul Sabatier Toulouse, Toulouse, France.;Department of Neurology and Neurosurgery, McGill University, Montreal, Canada. |
|---|
